FIT Biotech Oy

Company release July 18, 2017 at 4:00 pm

FIT Biotech Oy`s Board of Directors has decided on the issue of Convertible Notes and Warrants

On September 26, 2016, the Board of Directors of FIT Biotech Oy (hereinafter also the "Company") decided to establish Convertible Note and Warrant Programmes in order to implement the Convertible Notes with Warrants Funding Programme of up to EUR 12,480,000 between the Company and Bracknor Investment.

The Company`s Board of Directors decided yesterday to withdraw an eighth tranche of EUR 250,000 included in the Programme and to issue to Bracknor a total of 250 Convertible Notes and 6,887,052 Warrants, which entitle to subscribe for the Company`s K shares in accordance with the Terms and Conditions of the Convertible Notes and the Warrants.

FIT BIOTECH OY

Board of Directors

For further information:
Chairman of the Board of Directors Rabbe Slätis
Tel: +358 40 8406749
E-mail: rabbe.slatis@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FIT Biotech Oy via GlobeNewswire
HUG#2121116